5-(((4-bromopyridin-2-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione | 1198412-88-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(((4-bromopyridin-2-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione
• 英文别名: 5-[[(4-Bromo-2-pyridinyl)amino]methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione；5-[[(4-bromopyridin-2-yl)amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione
• CAS: 1198412-88-2
• 化学式: C₁₂H₁₁BrN₂O₄
• 分子量: 327.134
• InChiKey: HJNRQYHJEVRSLZ-UHFFFAOYSA-N

物化性质

• 熔点：
  228 °C
• 沸点：
  520.4±50.0 °C(Predicted)
• 密度：
  1.687±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  77.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-(((4-bromopyridin-2-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 在 四氧化锇 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 caesium carbonate 作用下， 以 四氢呋喃 、 二苯醚 、 水 、 叔丁醇 为溶剂， 反应 7.83h， 生成 4-oxo-4H-pyrido[1,2-a]pyrimidine-8-carbaldehyde
  参考文献：
  名称：

  [EN] SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME
  [FR] COMPOSÉS 1,1'-BIPHÉNYLE SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本发明包括取代的1,1'-联苯化合物，其类似物，以及包含它们的组合物。在一个方面，本发明中考虑的化合物可用于治疗、改善或预防患者体内的乙型肝炎病毒（HBV）和/或丙型肝炎病毒（HDV）感染。在另一个方面，本发明中考虑的化合物可用于治疗、改善和/或预防患者体内的癌症。

  公开号：

  WO2021158481A1
• 作为产物：
  描述：

  2-氨基-4-溴吡啶 、 5-乙氧基甲烯基-2,2-二甲基-1,3-二氧六环-4,6-二酮 以 乙醇 为溶剂， 生成 5-(((4-bromopyridin-2-yl)amino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione
  参考文献：
  名称：

  [EN] ACRYLAMIDE COMPOUND AND USE THEREOF
  [FR] COMPOSÉ D'ACRYLAMIDE ET SON UTILISATION
  [ZH] 丙烯酰胺类化合物及其应用

  摘要：

  一类丙烯酰胺类化合物及其应用，具体涉及式(I)所示化合物及其药学上可接受的盐。

  公开号：

  WO2023036217A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS D'UTILISATION
  申请人：INTEGRAL BIOSCIENCES PVT LTD

  公开号：WO2020012357A1

  公开（公告）日：2020-01-16

  The present invention discloses compounds useful in treatment of conditions associated with excessive activity of transforming growth factor beta (TGF-β), particularly type 1 or activin-like kinase 5 (ALK 5). Specifically the present invention discloses compound of formula (I) which exhibit inhibitory activity against ALK 5. Method of treating conditions associated with excessive activity (ALK 5) with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.

  本发明揭示了在治疗与转化生长因子β（TGF-β）过度活性相关的疾病中有用的化合物，特别是针对类型1或类活化激酶5（ALK 5）。具体来说，本发明揭示了具有对ALK 5具有抑制活性的化合物的结构式（I）。还公开了使用这种化合物治疗与过度活性（ALK 5）相关的疾病的方法。此外，还公开了这些化合物的用途、制药组合物和试剂盒。
• Synthesis of Halogenated 4H-Pyrido[1,2-a]pyrimidin-4-ones
  作者：István Hermecz、Annamária Molnár、Ferenc Faigl、Benjamin Podányi、Zoltán Finta、László Balázs

  DOI：10.3987/com-09-11746

  日期：——

  4-diones. The latters formed from N-(2-pyridyl)iminoketenes, the common intermediates of 4H-pyrido[1,2-a]pyrimidin-4-one and 1,8-naphthyridin-4-ones, via a "head-to-tail" [4+2] cycloaddition. 3-Halo-4H-pyrido[1,2-a]pyrimidin-4-ones were obtained from 4H-pyrido[1,2-a]pyrimidin-4-one with N-halosuccinimides. The structures of the new compounds were characterized by means of 1 H NMR and 13 C NMR examinations

  卤代 4H-pyrido[1,2-a]pyrimidin-4-one 是通过异亚丙基 (2-pyridylamino) 亚甲基丙二酸酯的热环化和脱羧合成的，由 2-氨基吡啶和原位形成的异亚丙基甲氧基亚甲基丙二酸酯制备。代替 4H-pyrido[1,2-a]pyrimidin-4-ones，6-氯和 6-溴衍生物提供 7-halo-1,4-dihydro-1,8-naphthyridin-4-ones 和1-(6-卤代-2-吡啶基)-3-[(6-卤代-2-吡啶基氨基)亚甲基]-1,2,3,4-四氢吡啶-2,4-二酮。后者由 N-(2-pyridyl)iminoketenes、4H-pyrido[1,2-a]pyrimidin-4-one 和 1,8-naphthyridin-4-ones 的常见中间体通过“头对- tail" [4+2] 环加成。3-Halo-4H-pyrido[1,2-a]pyrimidin-4-ones
• Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5)
  作者：Jeffrey G. Varnes、Andrew P. Marcus、Russell C. Mauger、Scott R. Throner、Valerie Hoesch、Megan M. King、Xia Wang、Linda A. Sygowski、Nathan Spear、Reto Gadient、Dean G. Brown、James B. Campbell

  DOI：10.1016/j.bmcl.2011.01.027

  日期：2011.3

  Novel in vitro mGlu(5) positive allosteric modulators with good potency, solubility, and low lipophilicity are described. Compounds were identified which did not rely on the phenylacetylene and carbonyl functionalities previously observed to be required for in vitro activity. Investigation of the allosteric binding requirements of a series of dihydroquinolinone analogs led to phenylacetylene azachromanone 4 (EC50 11.5 nM). Because of risks associated with potential metabolic and toxicological liabilities of the phenylacetylene, this moiety was successfully replaced with a phenoxymethyl group (27; EC50 156.3 nM). Derivation of a second-generation of mGlu(5) PAMs lacking a ketone carbonyl resulted in azaindoline (33), azabenzimidazole (36), and N-methyl 8-azaoxazine (39) phenylacetylenes. By scoping nitrogen substituents and phenylacetylene replacements in 39, we identified phenoxymethyl 8-azaoxazine 47 (EC50 50.1 nM) as a potent and soluble mGlu(5) PAM devoid of both undesirable phenylacetylene and carbonyl functionalities. (C) 2011 Elsevier Ltd. All rights reserved.
• SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME
  申请人：Arbutus Biopharma Corporation

  公开号：EP4100381A1

  公开（公告）日：2022-12-14
• HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  申请人：Integral Biosciences Private Limited

  公开号：US20200247812A1

  公开（公告）日：2020-08-06

  The present invention discloses compounds useful in treatment of conditions associated with excessive activity of transforming growth factor beta (TGF-β), particularly type I or activin-like kinase 5 (ALK 5). Specifically, the present invention discloses compound of formula (I) which exhibit inhibitory activity against ALK 5. Method of treating conditions associated with excessive activity (ALK 5) with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.